ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "infliximab and tocilizumab"

  • Abstract Number: 502 • ACR/ARHP Annual Meeting 2014

    Tocilizumab Use in Patients with Rheumatoid Arthritis Having Failed One Previous Anti-TNF Agent: Comparison with Adalimumab, Etanercept and Infliximab

    Denis Choquette1, Marie-Pier Payette1, Jean-Pierre Raynauld1, Jean-Pierre Pelletier2, Louis Bessette3, Edith Villeneuve1, Boulos Haraoui1, Isabelle Fortin4, Marie-Anaïs Rémillard5, Diane Sauvageau1 and Louis Coupal1, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 3Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, 4Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, 5Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada

    Background/Purpose : Tocilizumab, as an intra-venous agent, has been approved for rheumatoid arthritis (RA) in Canada in April 30th, 2010. It was the sixth approved…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology